ME01665B - Analozi buprenorfina - Google Patents

Analozi buprenorfina

Info

Publication number
ME01665B
ME01665B MEP-2014-12A MEP1214A ME01665B ME 01665 B ME01665 B ME 01665B ME P1214 A MEP1214 A ME P1214A ME 01665 B ME01665 B ME 01665B
Authority
ME
Montenegro
Prior art keywords
buprenorphine analogs
buprenorphine
analogs
abstract
Prior art date
Application number
MEP-2014-12A
Other languages
English (en)
Inventor
Donald J Kyle
R Richard Goehring
Marian E Fundytus
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of ME01665B publication Critical patent/ME01665B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone

Abstract

abstract
MEP-2014-12A 2008-07-30 2009-07-30 Analozi buprenorfina ME01665B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8476408P 2008-07-30 2008-07-30
US22611909P 2009-07-16 2009-07-16
PCT/US2009/004391 WO2010014229A1 (en) 2008-07-30 2009-07-30 Buprenorphine analogs
EP09789036.2A EP2326651B1 (en) 2008-07-30 2009-07-30 Buprenorphine analogs

Publications (1)

Publication Number Publication Date
ME01665B true ME01665B (me) 2014-09-20

Family

ID=41119539

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2014-12A ME01665B (me) 2008-07-30 2009-07-30 Analozi buprenorfina

Country Status (25)

Country Link
US (1) US8530494B2 (me)
EP (2) EP2703404A1 (me)
JP (2) JP5525524B2 (me)
KR (1) KR101343395B1 (me)
CN (2) CN103450206A (me)
AU (1) AU2009277095B2 (me)
CA (1) CA2731939C (me)
CO (1) CO6341635A2 (me)
DK (1) DK2326651T3 (me)
ES (1) ES2449222T3 (me)
HK (1) HK1158622A1 (me)
HR (1) HRP20140182T1 (me)
IL (1) IL210391A0 (me)
ME (1) ME01665B (me)
MX (1) MX2011001268A (me)
NZ (1) NZ590650A (me)
PL (1) PL2326651T3 (me)
PT (1) PT2326651E (me)
RS (1) RS53154B (me)
RU (2) RU2520222C2 (me)
SI (1) SI2326651T1 (me)
SM (1) SMT201400023B (me)
UA (1) UA104004C2 (me)
WO (1) WO2010014229A1 (me)
ZA (1) ZA201100188B (me)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2619212T3 (en) * 2010-09-21 2016-03-21 Purdue Pharma Lp BUPRENORPHINANALOGER AS opioid receptor agonists and / or antagonists
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
AU2012324012A1 (en) 2011-12-08 2013-06-27 Purdue Pharma L.P. Quaternized buprenorphine analogs
JP6400592B2 (ja) 2012-11-09 2018-10-03 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
TW201434842A (zh) * 2012-12-07 2014-09-16 Purdue Pharma Lp 丁基原啡因（ｂｕｐｒｅｎｏｒｐｈｉｎｅ）類似物類
JP6141444B2 (ja) 2012-12-14 2017-06-07 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環式モルフィナンおよびこれらの使用
EP2931724B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Pyridonemorphinan analogs and biological activity on opioid receptors
EP2941431B1 (en) * 2012-12-28 2017-10-25 Purdue Pharma L.P. Substituted morphinans and the use thereof
JP6182620B2 (ja) 2013-01-31 2017-08-16 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US9656962B2 (en) 2013-12-26 2017-05-23 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
WO2015100092A2 (en) * 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta analogs of orvinols
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
US10030021B2 (en) 2014-05-27 2018-07-24 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
JP6360915B2 (ja) 2014-06-13 2018-07-18 パーデュー、ファーマ、リミテッド、パートナーシップ アザモルフィナン誘導体及びその使用
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) * 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) * 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
NL289751A (me) 1962-03-02
GB1136764A (en) * 1965-08-13 1968-12-18 Reckitt & Sons Ltd Derivatives of thebaine and oripavine
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2230154A1 (de) 1972-06-21 1974-01-17 Boehringer Sohn Ingelheim N-(heteroaryl-methyl)-6,14-endoaetheno7alpha-hydroxyalkyl-tetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PT95069B (pt) 1989-08-24 1997-10-31 Searle & Co Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5552406A (en) 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
DE69826278T2 (de) 1997-05-30 2005-11-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazol-derivate
US6410561B1 (en) 1998-03-26 2002-06-25 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
KR20030088445A (ko) * 2001-03-02 2003-11-19 유로-셀티큐 에스.에이. Ｎ-부-3-테닐 노르부프레노르핀 및 사용방법
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
CN1939920B (zh) 2005-09-29 2011-08-31 中国人民解放军军事医学科学院毒物药物研究所 东罂粟碱类化合物及其医药用途

Also Published As

Publication number Publication date
WO2010014229A1 (en) 2010-02-04
SI2326651T1 (sl) 2014-03-31
EP2326651A1 (en) 2011-06-01
JP2014208640A (ja) 2014-11-06
US20110136846A1 (en) 2011-06-09
AU2009277095B2 (en) 2012-09-06
ES2449222T3 (es) 2014-03-18
CN102112479A (zh) 2011-06-29
JP5525524B2 (ja) 2014-06-18
PT2326651E (pt) 2014-02-12
CO6341635A2 (es) 2011-11-21
RU2520222C2 (ru) 2014-06-20
RS53154B (en) 2014-06-30
KR101343395B1 (ko) 2013-12-19
SMT201400023B (it) 2014-05-07
CA2731939A1 (en) 2010-02-04
RU2013106944A (ru) 2014-08-27
AU2009277095A1 (en) 2010-02-04
HK1158622A1 (en) 2012-07-20
US8530494B2 (en) 2013-09-10
CN103450206A (zh) 2013-12-18
DK2326651T3 (da) 2014-01-20
ZA201100188B (en) 2011-09-28
JP2012506839A (ja) 2012-03-22
PL2326651T3 (pl) 2014-05-30
HRP20140182T1 (hr) 2014-04-11
MX2011001268A (es) 2011-07-29
EP2703404A1 (en) 2014-03-05
CA2731939C (en) 2017-05-23
EP2326651B1 (en) 2013-11-27
KR20110036859A (ko) 2011-04-11
UA104004C2 (uk) 2013-12-25
IL210391A0 (en) 2011-03-31
NZ590650A (en) 2013-01-25
RU2011107440A (ru) 2012-09-10
CN102112479B (zh) 2014-10-29

Similar Documents

Publication Publication Date Title
ME01665B (me) Analozi buprenorfina
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CR20120295A (es) Triazolopiridinas
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CR20140024A (es) Compuestos inhibidores de metaloenzimas
UY34365A (es) Compuestos heterociclicos
DE112010003410T8 (de) Vorkammerzündkerze
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY33930A (es) Inhibidores novedosos de quinasas
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
BRPI0910345A2 (pt) análogos de oxitocina
CR20120637A (es) Triazolopiridinas sustituidas
DE102009047789A8 (de) Mischlichtquelle
IN2011KN03928A (me)
UY34312A (es) Compuesto de benzotiazolona
CL2009001973S1 (es) Mostrador.
FI20080112A0 (fi) Seos
CL2011000971S1 (es) Cepillo de dientes
TN2010000578A1 (fr) خلاط مياه بثلاث صمامات
TN2011000420A1 (fr) طريقة علمية لمقاومة التصحر وتخصيب الصحراء
CL2011001069S1 (es) Triciclo.
TN2010000567A1 (fr) المحطة الكهرمائية الشمسية
TN2010000017A1 (fr) مستحضر تجميلي دوائي
TN2011000287A1 (fr) حذاء مولد للطاقة
TN2011000162A1 (fr) نظام هندسي ومعماري مبتكر لانشاء البناء عامة ومواكب للتكنولوجيات المتطورة مادته الاساسية الطين والتربة